An interventional study of Peppermint Oil and cardomom oil in Cancer, sponsored by Semanur Bilgiç. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Semanur Bilgiç · Not applicable, Interventional, and Supportive care
The aim of this study is to evaluate the effect of inhaled cardamom oil on chemotherapy-related nausea, vomiting, and food intake and to compare these effects with those of inhaled peppermint oil.
Chemotherapy is an effective treatment method used to control cancer systemically by destroying cancer cells or controlling their growth. This treatment inhibits nucleic acid synthesis, thereby preventing DNA and RNA synthesis, and has both cytotoxic and anticancer properties. However, chemotherapy also affects rapidly dividing cells, leading to undesirable side effects. Among these, nausea and vomiting are common and quality-of-life-reducing side effects that affect approximately 80% of patients undergoing chemotherapy.
The pathophysiology of nausea and vomiting is based on mechanisms such as the stimulation of the vomiting center and the chemoreceptor trigger zone, as well as the stimulation of enterochromaffin cells and vagal afferent neurons. Failure to manage these symptoms can lead to serious problems such as malnutrition, dehydration, anorexia, and fluid-electrolyte imbalance. Therefore, antiemetic drugs and various integrative methods (acupuncture, acupressure, behavioral interventions, music therapy, relaxation exercises, hypnotherapy, and aromatherapy) are used to manage nausea and vomiting.
Aromatherapy with various essential oils such as peppermint, ginger, rose, cardamom, lavender, and chamomile has been found to be effective in preventing nausea and vomiting. The effect of peppermint oil on chemotherapy-related nausea and vomiting is well-documented; however, research on cardamom oil is limited. There are few studies in the literature evaluating the effect of cardamom oil on these symptoms. The aim of this study is to evaluate the effect of inhaled cardamom oil on chemotherapy-related nausea, vomiting, and food intake and to compare these effects with those of inhaled peppermint oil.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 39 is below the median of 60 across 7,703 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Semanur Bilgiç as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Other: Peppermint Oil
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Other: cardomom oil
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Other: sweet almond oil
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Thirty minutes before the chemotherapy session begins, one drop of essential oil will be applied to a piece of gauze. The gauze will then be attached to the patient's collar with a safety pin, positioned 20 cm away from the patient's nose. This procedure will be performed three times a day for five consecutive days.
Chemotherapy-Related Nausea-Vomiting and Retching
The Rhodes Index of Nausea, Vomiting and Retching (INVR) was developed by Rhodes and McDaniel in 1999 to assess nausea, vomiting, retching, and related distress experienced within the last 12 hours, particularly after chemotherapy. The scale consists of 8 items rated on a Likert-type scale, where 0 indicates minimal distress and 4 indicates severe distress. Items 1, 3, 6, and 7 are reverse-scored. The INVR includes three subdimensions: symptom experience, symptom occurrence, and symptom distress. The original scale demonstrated high internal consistency (Cronbach's alpha = 0.98; subscales = 0.83-0.99).
Time frame: five consecutive days.
Food Intake
Food Consumption Form: The 24-hour dietary recall method is used to record food intake. In this study, patients record all foods and beverages consumed over five consecutive days. Portions are documented using household measures such as cups, glasses, mugs, and spoons.
Time frame: five consecutive days.
Chemotherapy-Related Nausea
Visual Analog Scale (VAS): The severity of nausea will be assessed using a 100-mm Visual Analog Scale (VAS), where the left end represents "no nausea" and the right end represents "severe nausea." A score \<5 mm is defined as no nausea, and a 10-mm difference is typically considered clinically significant.
Time frame: five consecutive days.
Food Frequency Form
This form identifies the food groups consumed by the patient over the five-day period. It verifies the information recorded in the food consumption form and provides insight into the patient's dietary patterns. The food frequency method is commonly used to assess relationships between diet and disease risk.
Time frame: five consecutive days.
Anthropometric Measurements1
Body mass index (BMI) is calculated by dividing weight in kilograms by height in meters squared (kg/height²).
Time frame: Measurements will be taken twice, on the first and fifth days.
Anthropometric Measurements2
Skinfold thickness measurements are taken using calipers and are used to rank individuals in terms of relative total "fatness" or to assess subcutaneous fat in various areas of the body.
Time frame: Measurements will be taken twice, on the first and fifth days.
Anthropometric Measurements3
waist and hip circumference: Using a tape measure, measure around the narrowest part of the waist, just above the belly button. This is the waist circumference. Measure around the widest part of the hips. This is the hip circumference.
Time frame: Measurements will be taken twice, on the first and fifth days.
Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.
Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 5 months is below that.
Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.